SELLAS Life Sciences Group, Inc.
Complete interim analysis of the Phase 3 REGAL AML study
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 1 Jun 2023
- Due
- 31 Dec 2023
- Delivered
- January 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“We expect our interim analysis by the end of this year or early next”
What we found
Evidence strength A What the grades mean
The company expected the interim analysis by the end of 2023 or early 2024, but the analysis was not completed until January 2025.
-
A SELLAS Life Sciences Group, Inc. 10-K filed 2025-03-20
“In January 2025, we announced that the IDMC had completed pre-specified interim analysis of the REGAL study” ✓ confirmed on the page
Market reaction: the shares moved +0.1% against the S&P 500 over the three sessions around the disclosure (19 Mar 2025 to 24 Mar 2025). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +182 days
- 2 versions
-
Version 1 · original · stated 1 Jun 2023
Deadline 31 Dec 2023 (“by the end of this year”) · wording expected
-
Version 2 · stated 28 Mar 2024
Deadline 30 Jun 2024 (“1H 2024”) · wording expected
“Anticipated interim analysis of the ongoing global Phase 3 registrational clinical trial (the REGAL study) of GPS in patients with AML... in 1H 2024.”
-
Version 3 · stated 28 Mar 2024
Deadline 31 Dec 2024 (“by the end of 2024”) · wording expected
“Final analysis expected to occur by the end of 2024.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- Interim analysis of Phase 3 REGAL AML study
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you SELLAS Life Sciences Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-SLS-002014 · Corrections policy